Tag: ASX: AVR
$38.5M investment to expand Anteris’ manufacturing capacity, global clinical program
Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
Anteris marks first successful implantation of DurAVR THV heart valve
ASX-listed biotechnology company Anteris Technologies has announced the successful use of its DurAVR THV biomimetic valve in a valve-in-valve (ViV) procedure.
Anteris awarded utility patent for novel transcatheter heart valve replacement
Australian biotechnology company Anteris Technologies announced that the US Patent and Trademark Office has issued another utility patent for its novel DurAVR transcatheter heart valve (THV).
Anteris Technologies to help develop new heart valve repair solution
Australian biotech company Anteris Technologies has collaborated with v2vmedtech to develop a new heart valve repair device designed for minimally invasive treatment of mitral and tricuspid valve regurgitation.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
FDA OKs manufacturing of Anteris’ aortic valve replacement at Minnesota facility
Anteris Technologies announced that the US Food and Drug Administration (FDA) has approved the manufacturing of DurAVR THV, a 3D single-piece aortic heart valve replacement, at the company's recently expanded production facility in Maple Grove, Minnesota.
Featured Article
Australian Manufacturing Week 2026 to make Brisbane debut
Australia’s leading advanced manufacturing showcase, Australian Manufacturing Week (AMW), is set to return in 2026, marking its first-ever event in Brisbane.
